Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 9
2003 8
2004 7
2005 6
2006 5
2007 5
2008 9
2009 13
2010 11
2011 12
2012 11
2013 14
2014 9
2015 8
2016 15
2017 15
2018 5
2019 6
2020 1
2021 3
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-penetrating peptides.
Teesalu T, Sugahara KN, Ruoslahti E. Teesalu T, et al. Among authors: ruoslahti e. Front Oncol. 2013 Aug 27;3:216. doi: 10.3389/fonc.2013.00216. eCollection 2013. Front Oncol. 2013. PMID: 23986882 Free PMC article.
Molecular ZIP codes in targeted drug delivery.
Ruoslahti E. Ruoslahti E. Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2200183119. doi: 10.1073/pnas.2200183119. Epub 2022 Jun 30. Proc Natl Acad Sci U S A. 2022. PMID: 35771944 Free PMC article. Review.
In vivo selection of tumor-specific antibodies.
Sánchez-Martín D, Sanz L, Ruoslahti E, Alvarez-Vallina L. Sánchez-Martín D, et al. Among authors: ruoslahti e. Oncotarget. 2013 Oct;4(10):1547. doi: 10.18632/oncotarget.1407. Oncotarget. 2013. PMID: 24077798 Free PMC article. No abstract available.
Tumor penetrating peptides for improved drug delivery.
Ruoslahti E. Ruoslahti E. Adv Drug Deliv Rev. 2017 Feb;110-111:3-12. doi: 10.1016/j.addr.2016.03.008. Epub 2016 Apr 1. Adv Drug Deliv Rev. 2017. PMID: 27040947 Free PMC article. Review.
Specialization of tumour vasculature.
Ruoslahti E. Ruoslahti E. Nat Rev Cancer. 2002 Feb;2(2):83-90. doi: 10.1038/nrc724. Nat Rev Cancer. 2002. PMID: 12635171 Review.
Bit1 in anoikis resistance and tumor metastasis.
Jenning S, Pham T, Ireland SK, Ruoslahti E, Biliran H. Jenning S, et al. Among authors: ruoslahti e. Cancer Lett. 2013 Jun 10;333(2):147-51. doi: 10.1016/j.canlet.2013.01.043. Epub 2013 Jan 31. Cancer Lett. 2013. PMID: 23376255 Free PMC article. Review.
Drug targeting to specific vascular sites.
Ruoslahti E. Ruoslahti E. Drug Discov Today. 2002 Nov 15;7(22):1138-43. doi: 10.1016/s1359-6446(02)02501-1. Drug Discov Today. 2002. PMID: 12546857 Review.
Targeted Antiscarring Therapy for Tissue Injuries.
Järvinen TA, Ruoslahti E. Järvinen TA, et al. Among authors: ruoslahti e. Adv Wound Care (New Rochelle). 2013 Mar;2(2):50-54. doi: 10.1089/wound.2011.0299. Adv Wound Care (New Rochelle). 2013. PMID: 24527325 Free PMC article. Review.
163 results